Kalaris TherapeuticsKLRS
13F holders, Q1 2025 (March 31)32holders
2famous investors
$8.03avg. 13F price*
At the end of Q1 2025, 32 institutions reported holding Kalaris Therapeutics Inc. (KLRS) in their 13F filings. The largest holders were Samsara Biocapital, LLC ($91.9M), Gilead Sciences, Inc. ($5.8M) and Octagon Capital Advisors LP ($3.9M). 2 famous investors held it, including Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio) and Israel Englander (0.0% of Millennium Management's portfolio).
- Company
- Kalaris Therapeutics Inc.
- CUSIP
- 482929106
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 32 | $111.4M |
| Exits | 0 | $0 |
Ownership 32 holders
| Samsara Biocapital, LLC | 16.39% | New | 11,448,081 | $91.9M |
| Gilead Sciences, Inc. | 0.49% | New | 723,273 | $5.8M |
| Octagon Capital Advisors LP | 0.84% | New | 481,000 | $3.9M |
| Tang Capital Management LLC | 0.14% | New | 309,221 | $2.5M |
| Siren, L.L.C. | 0.13% | New | 282,586 | $2.3M |
| EcoR1 Capital, LLC | 0.10% | New | 201,718 | $1.6M |
| Vanguard Group Inc. | 0.00% | New | 115,086 | $924K |
| Redmile Group, LLC | 0.06% | New | 82,955 | $666K |
| BlackRock, Inc. | 0.00% | New | 27,514 | $221K |
| Geode Capital Management, LLC | 0.00% | New | 26,787 | $215K |
| Two Sigma Advisers, LP | 0.00% | New | 21,581 | $173K |
| Woodline Partners LP | 0.00% | New | 21,519 | $173K |
| Renaissance Technologies | 0.00% | New | 19,251 | $155K |
| RBF Capital, LLC | 0.01% | New | 17,391 | $140K |
| Millennium Management | 0.00% | New | 16,582 | $133K |
| Squarepoint Ops LLC | 0.00% | New | 14,587 | $117K |
| Marshall Wace, LLP | 0.00% | New | 14,115 | $113K |
| Susquehanna International Group, LLP | 0.00% | New | 13,796 | $111K |
| State Street Corp. | 0.00% | New | 10,710 | $86K |
| UBS Group AG | 0.00% | New | 9,261 | $74K |
| FMR LLC | 0.00% | New | 7,806 | $63K |
| Bank of America Corp. | 0.00% | New | 5,424 | $44K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 1,434 | $12K |
| Morgan Stanley | 0.00% | New | 1,296 | $10K |
| Federated Hermes, Inc. | 0.00% | New | 634 | $5K |
| JPMorgan Chase & Co. | 0.00% | New | 295 | $2K |
| Coldstream Capital Management Inc. | 0.00% | New | 208 | $2K |
| BNP Paribas Financial Markets | 0.00% | New | 127 | $1K |
| Parallel Advisors, LLC | 0.00% | New | 49 | $393 |
| Farther Finance Advisors, LLC | 0.00% | New | 33 | $264 |
| EverSource Wealth Advisors, LLC | 0.00% | New | 30 | $241 |
| Barclays PLC | 0.00% | New | 1 | $8 |
"% of holder's portfolio" is KLRS's weight in each manager's 13F, not the share of Kalaris Therapeutics Inc. the manager owns.